Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

New Research Platform Seeks Parkinson’s Patients in Canada

Parkinson Canada is inviting patients to join the Canadian Open Parkinson Network (C-OPN) to help advance Parkinson’s disease care and research. The national research platform seeks to drive more efficient research, accelerate disease understanding, and uncover new treatments for the neurodegenerative disorder. The hope is to facilitate rapid…

Supernus Acquires Apokyn and Xadago from US WorldMeds

Supernus Pharmaceuticals’ acquisition of US WorldMeds’ portfolio of central nervous system (CNS) disease treatments adds two established Parkinson’s disease (PD) therapies and a leading investigative product to its neurology portfolio. The deal calls for a $300 million upfront cash outlay, plus $230 million in milestone payments for…

Parkinson’s Voice Project Grant Enables Speak Out! and Loud Crowd Program

Parkinson Voice Project has given a second grant to the Speech-Language Institute (SLI) at Salus University, enabling it to continue its SPEAK OUT! & LOUD Crowd therapy programs. Through the grant — the amount was not specified — the SLI will continue offering free group speech therapy to Parkinson’s patients…

Accure Therapeutics Launches with Focus on Nervous System Disorders

Accure Therapeutics announced its opening, supported by €7.6 million (about $8.1 million) in Series A funding. The Barcelona, Spain-based pharmaceutical company will focus on developing treatment candidates for central nervous system (CNS) disorders such as Parkinson’s disease. The funding round was led by Alta Life Sciences, and…

MJFF Offering Webinar Series for Scientists and Clinicians

The Michael J. Fox Foundation (MJFF) is offering a new online Parkinson’s disease educational series aimed at researchers and clinicians. Parkinson’s Disease Therapeutics Webinars, a free four-part series, starts June 16 and will feature presentations by leaders in Parkinson’s research and treatment development. “We know people with…

MJFF Suggests Ways to Help Advance Clinical Trials During Pandemic

With numerous clinical trials interrupted due to the COVID-19 pandemic, The Michael J. Fox Foundation (MJFF) is highlighting online ways that Parkinson’s (PD) patients and others can help to advance research. People are necessarily spending more time at home, but study participation remains crucial to treatment development. Even before…

Parkinson’s Foundation, VA Join to Help US Veterans Manage Disease

The Parkinson’s Foundation and the U.S. Department of Veterans Affairs (VA) are collaborating on an effort to improve the health and life quality of veterans with Parkinson’s disease. The two want to provide people who served in the U.S. Armed Forces with better resources and ways to manage Parkinson’s, a…